Published: 2017-07-22

A drug utilization study in glaucoma patients in ophthalmology out patient department in a tertiary care hospital

Kaushal B. Patel, Gurusharan H. Dumra, Adarsh Jeet Singh, Abhishek Vyas, Chetan G. Parmar


Background: According to World Health Organization (WHO) studies Glaucoma is a chronic progressive symptomatic disease that damages retinal cells and is one of the leading cause of preventable blindness worldwide. Availability of newer topical agents has modernized the management of glaucoma.

Methods: A prospective observational study was carried out from August 2016 to December 2016 at ophthalmology Out Patient Department of L.G General Hospital, Ahmedabad by authours after the approval of the Institutional Ethics Committee.

Results: Out of total 101 patients, 71 were males and 30 were females. Average age of patient is 54 years. Common variant of Glaucoma was Primary Open Angle Glaucoma in 57.4% of patients. Average number of drugs per prescription was 2 (45%). Most commonly used Fixed Dose Combination was Brimonidine +Timolol Drops which was used in 87 (86.1%) patients. Most commonly used adjuvant drug was Tab. Acetazolamide (60% of patients).

Conclusions: Common variant of Glaucoma was Primary Open Angle Glaucoma in 57.4% of patients. Most commonly used Fixed Dose Combination was Brimonidine+Timolol Drops which was used in 87 (86.1%) patients and commonly used Single drug therapy is Tab. Acetazolamide in (60% of patients).


Angle closure glaucoma, Chronic narrow angle glaucoma, Drug utilization study, Narrow angle glaucoma, Prescription analysis, Primary open angle glaucoma

Full Text:



World Health Organization. The selection of essential drugs WHO technical report. Switzerland. 1977;615:36.

An assessment of the Health and Economic Burden of Glaucoma, American Journal of Ophthalmology. Oct 2011;152(4):515-22.

Melrose D. Double deprivation public and private drug distribution from the perspective of the third world's poor. World Dev. 1983;11:181-6.

Mayo Clinic. Cited 2017 April. Available at: conditions/glaucoma/basics/risk-factors/con-20024042" conditions/glaucoma/basics/risk-factors/con-20024042.

Friedman DS, Hahn SR, Gelb L, Tan J, Shah SN, Kim EE, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma: Results from the glaucoma adherence and persistency study. Ophthalmology. 2008 Aug 31;115(8):1320-7.

Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Current Opinion in Ophthalmology. 2006;17(2):190-5.

Sleath AL. Covert RD, Byrd JE, Tudor G, Svarstad B. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113(3):431-6.

Krishnaswamy K, Dinesh KB, Radhaiah G. A drug survey precepts and practices. Eur J Clin Pharmacol. 1985;29:363-70.

Dandona L, Dandona R, Srinivas M, Mandal P, John RK, McCarty CA, et al. Open-angle glaucoma in an urban population in southern India: the Andhra Pradesh eye disease study. Ophthalmology. 2000 Sep 30;107(9):1702-9.

Prajwal P, Rai M, Gopalakrishna HN, Kateel R. An Exploratory Study on the Drug Utilization Pattern in Glaucoma Patients at A Tertiary Care Hospital. J App Pharm Sci. 2013;3(10):151-5.

Yadav AK, Patel V. Drug use in primary open angle glaucoma: A prospective study at a tertiary care teaching hospital. Indian J Pharmacol. 2013;45:117-20.

Gilman AG, Rall TW, Nies AS. Principles of therapeutics. In the Pharmacological Basis of Therapeutics 8th Edition, eds. New York; Pergamon Press; 1990:62-83.

All India Opthalmological Society. Cited 2017 April. Available at: